Oana Danciu, MD, is Associate Director of Clinical Research at the University of Illinois Cancer Center, a breast oncologist at UI Health and Associate Professor in the Division of Hematology and Oncology at the University of Illinois College of Medicine Chicago. Her research is focused on breast cancer, early phase clinical trials development and experimental therapeutics. Her work has been presented at major national conferences, including the American Society of Clinical Oncology (ASCO) Breast Cancer Symposium, San Antonio Breast Cancer Symposium and ASCO Cancer Survivorship Symposium. Her extensive work includes developing a Phase I protocol with a new experimental agent, PAC-1 (first procaspase activating compound). PAC-1 is a small molecule that directly activates procaspase-3 and induces apoptosis of cancer cells. Additionally, she represents the University of Illinois Chicago (UIC) in the Big Ten Cancer Research Consortium Breast Cancer Working, and this has led to collaborations outside the institution with nationally recognized breast oncologists. Her trial, “A Single Arm Phase II Study of Palbociclib in Combination with Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer,” was awarded by Pfizer as part of the ASPIRE program.
Oana Danciu, MD
Associate Professor
Department of Medicine, Division of Hematology/Oncology
University of Illinois College of Medicine Chicago
Research Program
Translational Oncology Program (TO)
Phone: 312-996-1581
Email: [email protected]
